25 XP   0   0   10

Titan Pharmaceuticals Inc
Buy, Hold or Sell?

Let's analyse Titan Pharmaceuticals Inc together

PenkeI guess you are interested in Titan Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Titan Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Titan Pharmaceuticals Inc

I send you an email if I find something interesting about Titan Pharmaceuticals Inc.

Quick analysis of Titan Pharmaceuticals Inc (30 sec.)










What can you expect buying and holding a share of Titan Pharmaceuticals Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
2.5%

What is your share worth?

Current worth
$7.27
Expected worth in 1 year
$14.87
How sure are you?
35.0%

+ What do you gain per year?

Total Gains per Share
$7.61
Return On Investment
107.1%

For what price can you sell your share?

Current Price per Share
$7.10
Expected price per share
$5.25 - $9.07
How sure are you?
50%

1. Valuation of Titan Pharmaceuticals Inc (5 min.)




Live pricePrice per Share (EOD)

$7.10

Intrinsic Value Per Share

$-150.53 - $-50.11

Total Value Per Share

$-143.26 - $-42.84

2. Growth of Titan Pharmaceuticals Inc (5 min.)




Is Titan Pharmaceuticals Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$6.6m$2.5m$2.5m49.6%

How much money is Titan Pharmaceuticals Inc making?

Current yearPrevious yearGrowGrow %
Making money-$1.4m-$2.3m$867.4k59.2%
Net Profit Margin-41,762.5%-18,549.4%--

How much money comes from the company's main activities?

3. Financial Health of Titan Pharmaceuticals Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#724 / 1016

Most Revenue
#714 / 1016

Most Profit
#268 / 1016

Most Efficient
#988 / 1016

What can you expect buying and holding a share of Titan Pharmaceuticals Inc? (5 min.)

Welcome investor! Titan Pharmaceuticals Inc's management wants to use your money to grow the business. In return you get a share of Titan Pharmaceuticals Inc.

What can you expect buying and holding a share of Titan Pharmaceuticals Inc?

First you should know what it really means to hold a share of Titan Pharmaceuticals Inc. And how you can make/lose money.

Speculation

The Price per Share of Titan Pharmaceuticals Inc is $7.1. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Titan Pharmaceuticals Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Titan Pharmaceuticals Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $7.27. Based on the TTM, the Book Value Change Per Share is $1.90 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.27 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Titan Pharmaceuticals Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-2.15-30.3%-1.60-22.6%-1.24-17.5%-1.40-19.7%-1.49-21.0%
Usd Book Value Change Per Share0.000.0%1.9026.8%-0.27-3.8%-0.01-0.1%0.060.9%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.010.1%
Usd Total Gains Per Share0.000.0%1.9026.8%-0.27-3.8%-0.01-0.1%0.071.0%
Usd Price Per Share7.16-2.17-0.81-1.36-1.79-
Price to Earnings Ratio-0.83--0.32--0.61--0.89--0.51-
Price-to-Total Gains Ratio-0.34--1.97--1.50--0.90-
Price to Book Ratio0.99-0.13-0.97-1.14-0.74-
Price-to-Total Gains Ratio-0.34--1.97--1.50--0.90-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share7.1
Number of shares140
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share1.90-0.01
Usd Total Gains Per Share1.90-0.01
Gains per Quarter (140 shares)266.22-1.45
Gains per Year (140 shares)1,064.89-5.79
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10106510550-6-16
20213021200-12-22
30319531850-17-28
40426042500-23-34
50532453150-29-40
60638963800-35-46
70745474450-41-52
80851985100-46-58
90958495750-52-64
10010649106400-58-70

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%4.036.00.010.0%9.0104.00.08.0%
Book Value Change Per Share1.02.01.025.0%3.08.01.025.0%7.012.01.035.0%13.024.03.032.5%33.075.05.029.2%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%1.00.039.02.5%1.00.0112.00.9%
Total Gains per Share1.02.01.025.0%3.08.01.025.0%7.012.01.035.0%14.024.02.035.0%34.075.04.030.1%

Fundamentals of Titan Pharmaceuticals Inc

About Titan Pharmaceuticals Inc

Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in the United States, Canada, and the European Union. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder; and other programs, including HIV preventative therapeutic and a contraceptive from a single ProNeura implant for women and adolescent girls. The company was incorporated in 1992 and is based in South San Francisco, California.

Fundamental data was last updated by Penke on 2024-04-12 20:39:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Titan Pharmaceuticals Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Titan Pharmaceuticals Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Titan Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Titan Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-41,762.5%+41,762.5%
TTM-41,762.5%YOY-18,549.4%-23,213.1%
TTM-41,762.5%5Y-12,454.9%-29,307.6%
5Y-12,454.9%10Y-7,589.9%-4,865.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--197.2%+197.2%
TTM-41,762.5%-210.4%-41,552.1%
YOY-18,549.4%-279.3%-18,270.1%
5Y-12,454.9%-436.8%-12,018.1%
10Y-7,589.9%-599.3%-6,990.6%
1.1.2. Return on Assets

Shows how efficient Titan Pharmaceuticals Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Titan Pharmaceuticals Inc to the Biotechnology industry mean.
  • -24.4% Return on Assets means that Titan Pharmaceuticals Inc generated $-0.24 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Titan Pharmaceuticals Inc:

  • The MRQ is -24.4%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -61.9%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-24.4%TTM-61.9%+37.5%
TTM-61.9%YOY-52.8%-9.0%
TTM-61.9%5Y-46.5%-15.4%
5Y-46.5%10Y-31.3%-15.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-24.4%-13.6%-10.8%
TTM-61.9%-12.9%-49.0%
YOY-52.8%-11.9%-40.9%
5Y-46.5%-14.2%-32.3%
10Y-31.3%-16.2%-15.1%
1.1.3. Return on Equity

Shows how efficient Titan Pharmaceuticals Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Titan Pharmaceuticals Inc to the Biotechnology industry mean.
  • -29.7% Return on Equity means Titan Pharmaceuticals Inc generated $-0.30 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Titan Pharmaceuticals Inc:

  • The MRQ is -29.7%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -15.9%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-29.7%TTM-15.9%-13.8%
TTM-15.9%YOY-76.6%+60.7%
TTM-15.9%5Y-64.4%+48.5%
5Y-64.4%10Y-69.0%+4.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-29.7%-17.0%-12.7%
TTM-15.9%-16.1%+0.2%
YOY-76.6%-15.4%-61.2%
5Y-64.4%-20.0%-44.4%
10Y-69.0%-21.1%-47.9%

1.2. Operating Efficiency of Titan Pharmaceuticals Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Titan Pharmaceuticals Inc is operating .

  • Measures how much profit Titan Pharmaceuticals Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Titan Pharmaceuticals Inc to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Titan Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-63,406.3%+63,406.3%
TTM-63,406.3%YOY-18,638.6%-44,767.7%
TTM-63,406.3%5Y-16,780.7%-46,625.6%
5Y-16,780.7%10Y-9,895.1%-6,885.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--286.1%+286.1%
TTM-63,406.3%-224.4%-63,181.9%
YOY-18,638.6%-288.4%-18,350.2%
5Y-16,780.7%-475.2%-16,305.5%
10Y-9,895.1%-624.7%-9,270.4%
1.2.2. Operating Ratio

Measures how efficient Titan Pharmaceuticals Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Titan Pharmaceuticals Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM638.250-638.250
TTM638.250YOY190.551+447.699
TTM638.2505Y169.983+468.267
5Y169.98310Y112.698+57.285
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.997-2.997
TTM638.2503.247+635.003
YOY190.5513.766+186.785
5Y169.9835.675+164.308
10Y112.6987.857+104.841

1.3. Liquidity of Titan Pharmaceuticals Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Titan Pharmaceuticals Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 5.55 means the company has $5.55 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Titan Pharmaceuticals Inc:

  • The MRQ is 5.553. The company is very able to pay all its short-term debts. +2
  • The TTM is 4.170. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ5.553TTM4.170+1.383
TTM4.170YOY1.835+2.335
TTM4.1705Y2.770+1.400
5Y2.77010Y3.032-0.261
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.5533.930+1.623
TTM4.1704.251-0.081
YOY1.8355.436-3.601
5Y2.7706.045-3.275
10Y3.0326.363-3.331
1.3.2. Quick Ratio

Measures if Titan Pharmaceuticals Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Titan Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Quick Ratio of 5.41 means the company can pay off $5.41 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Titan Pharmaceuticals Inc:

  • The MRQ is 5.415. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 2.666. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ5.415TTM2.666+2.749
TTM2.666YOY1.473+1.193
TTM2.6665Y2.120+0.546
5Y2.12010Y2.609-0.489
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.4153.629+1.786
TTM2.6664.065-1.399
YOY1.4735.397-3.924
5Y2.1205.993-3.873
10Y2.6096.277-3.668

1.4. Solvency of Titan Pharmaceuticals Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Titan Pharmaceuticals Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Titan Pharmaceuticals Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.18 means that Titan Pharmaceuticals Inc assets are financed with 17.9% credit (debt) and the remaining percentage (100% - 17.9%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Titan Pharmaceuticals Inc:

  • The MRQ is 0.179. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.704. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.179TTM0.704-0.526
TTM0.704YOY0.640+0.064
TTM0.7045Y0.663+0.041
5Y0.66310Y0.626+0.037
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1790.332-0.153
TTM0.7040.334+0.370
YOY0.6400.268+0.372
5Y0.6630.366+0.297
10Y0.6260.390+0.236
1.4.2. Debt to Equity Ratio

Measures if Titan Pharmaceuticals Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Titan Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 21.7% means that company has $0.22 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Titan Pharmaceuticals Inc:

  • The MRQ is 0.217. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.166. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.217TTM0.166+0.051
TTM0.166YOY0.803-0.637
TTM0.1665Y0.972-0.806
5Y0.97210Y1.651-0.679
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2170.381-0.164
TTM0.1660.390-0.224
YOY0.8030.334+0.469
5Y0.9720.434+0.538
10Y1.6510.466+1.185

2. Market Valuation of Titan Pharmaceuticals Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Titan Pharmaceuticals Inc generates.

  • Above 15 is considered overpriced but always compare Titan Pharmaceuticals Inc to the Biotechnology industry mean.
  • A PE ratio of -0.83 means the investor is paying $-0.83 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Titan Pharmaceuticals Inc:

  • The EOD is -0.824. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.831. Based on the earnings, the company is expensive. -2
  • The TTM is -0.323. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.824MRQ-0.831+0.007
MRQ-0.831TTM-0.323-0.508
TTM-0.323YOY-0.615+0.292
TTM-0.3235Y-0.885+0.562
5Y-0.88510Y-0.506-0.380
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.824-2.315+1.491
MRQ-0.831-2.560+1.729
TTM-0.323-2.664+2.341
YOY-0.615-4.122+3.507
5Y-0.885-6.258+5.373
10Y-0.506-6.108+5.602
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Titan Pharmaceuticals Inc:

  • The EOD is -0.722. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.728. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -0.240. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.722MRQ-0.728+0.006
MRQ-0.728TTM-0.240-0.488
TTM-0.240YOY-0.851+0.611
TTM-0.2405Y-0.872+0.631
5Y-0.87210Y-0.529-0.342
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.722-3.067+2.345
MRQ-0.728-3.251+2.523
TTM-0.240-3.545+3.305
YOY-0.851-5.595+4.744
5Y-0.872-8.315+7.443
10Y-0.529-8.708+8.179
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Titan Pharmaceuticals Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 0.99 means the investor is paying $0.99 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Titan Pharmaceuticals Inc:

  • The EOD is 0.977. Based on the equity, the company is cheap. +2
  • The MRQ is 0.986. Based on the equity, the company is cheap. +2
  • The TTM is 0.131. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD0.977MRQ0.986-0.008
MRQ0.986TTM0.131+0.854
TTM0.131YOY0.973-0.842
TTM0.1315Y1.143-1.012
5Y1.14310Y0.736+0.407
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.9771.905-0.928
MRQ0.9862.111-1.125
TTM0.1312.095-1.964
YOY0.9732.836-1.863
5Y1.1433.443-2.300
10Y0.7363.794-3.058
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Titan Pharmaceuticals Inc.

3.1. Institutions holding Titan Pharmaceuticals Inc

Institutions are holding 5.506% of the shares of Titan Pharmaceuticals Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-09-30BB&T Corp.4.14890.000562508900
2023-09-30Renaissance Technologies Corp0.90080.00011357101000.0737
2023-09-30Geode Capital Management, LLC0.58370879452398037.4893
2023-09-30Vanguard Group Inc0.544608205100
2023-09-30Susquehanna International Group, LLP0.4125062145621450
2023-09-30State Street Corporation0.254103828700
2023-09-30Tower Research Capital LLC0.01040157300
2023-09-30Level Financial Advisors, Inc.0.00660.000398700
2023-09-30Group One Trading, LP0.00150230-100-30.303
2023-09-30Bank of America Corp0.0014020600
2023-09-30JPMorgan Chase & Co0.001015796157.377
2023-09-30Wells Fargo & Co0.000608411.2048
2023-09-30BlackRock Inc0.000406000
2023-09-30Advisor Group Holdings, Inc.0.00030501335.1351
2023-12-31Global Wealth Strategies & Associates0.000304000
2023-09-30Morgan Stanley - Brokerage Accounts0.000101600
2023-09-30Westside Investment Management, Inc.00400
2023-09-30UBS Group AG00440
2023-09-30Qube Research & Technologies00440
2023-09-30McClarren Financial Advisors, Inc.00330
Total 6.86720.00091034645+86246+8.3%

3.2. Funds holding Titan Pharmaceuticals Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31NT Ext Equity Mkt Idx Fd - L0.03620584600
2023-12-31Northern Trust Extended Eq Market Idx0.03620584600
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr0.50810410300
2023-12-31NT Ext Equity Mkt Idx Fd - NL0.01990321700
2023-12-31SSgA U.S. Extended Market Index Class I0.01920.0001310000
2024-02-29Fidelity Extended Market Index0.3510.00012834-14-0.4916
2023-12-31NT Ext Equity Mkt Idx Fd - DC - NL - T20.0160258450.1939
2024-02-29Fidelity Nasdaq Composite Index0.11930.000196300
2023-12-31SSgA U.S. Total Market Index Strategy0.00550894-21-2.2951
2024-02-29Fidelity Series Total Market Index0.0648052300
2023-12-31NT US Market Cap Idx Fd - L0.0027043400
2023-12-31Northern Trust Wilshire 50000.0027043400
2024-03-31State St US Extended Mkt Indx NL Cl C0.01920.000115500
2023-12-31NT Ext Eq Mkt Indx Fd DC Lending Tier 50.0006010400
2024-02-29Spartan Total Market Index Pool E0.008106500
2024-02-29Spartan Extended Market Index Pool E0.0017014140
Total 1.21120.000431116-16-0.1%

3.3. Insider Transactions

Insiders are holding 45.469% of the shares of Titan Pharmaceuticals Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-06-21David E. LazarSELL16944524.6

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Titan Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---1.902-100%-0.2690%-0.0100%0.065-100%
Book Value Per Share--7.2655.574+30%0.452+1509%1.379+427%4.292+69%
Current Ratio--5.5534.170+33%1.835+203%2.770+100%3.032+83%
Debt To Asset Ratio--0.1790.704-75%0.640-72%0.663-73%0.626-71%
Debt To Equity Ratio--0.2170.166+31%0.803-73%0.972-78%1.651-87%
Dividend Per Share----0%-0%-0%0.008-100%
Eps---2.155-1.604-26%-1.244-42%-1.400-35%-1.492-31%
Free Cash Flow Per Share---2.459-2.035-17%-1.015-59%-1.391-43%-1.634-34%
Free Cash Flow To Equity Per Share---2.0150.810-349%0.348-680%0.049-4194%0.268-850%
Gross Profit Margin--1.0021.000+0%1.000+0%1.040-4%1.035-3%
Intrinsic Value_10Y_max---50.110--------
Intrinsic Value_10Y_min---150.526--------
Intrinsic Value_1Y_max---4.444--------
Intrinsic Value_1Y_min---8.039--------
Intrinsic Value_3Y_max---13.792--------
Intrinsic Value_3Y_min---30.399--------
Intrinsic Value_5Y_max---23.671--------
Intrinsic Value_5Y_min---59.431--------
Market Cap6491061.400-1%6545915.4401986790.473+229%6231290.116+5%7981586.738-18%5007791.842+31%
Net Profit Margin----417.6250%-185.4940%-124.5490%-75.8990%
Operating Margin----634.0630%-186.3860%-167.8070%-98.9510%
Operating Ratio---638.250-100%190.551-100%169.983-100%112.698-100%
Pb Ratio0.977-1%0.9860.131+652%0.973+1%1.143-14%0.736+34%
Pe Ratio-0.824+1%-0.831-0.323-61%-0.615-26%-0.885+7%-0.506-39%
Price Per Share7.100-1%7.1602.173+229%0.813+781%1.355+428%1.790+300%
Price To Free Cash Flow Ratio-0.722+1%-0.728-0.240-67%-0.851+17%-0.872+20%-0.529-27%
Quick Ratio--5.4152.666+103%1.473+268%2.120+155%2.609+108%
Return On Assets---0.244-0.619+154%-0.528+117%-0.465+91%-0.313+29%
Return On Equity---0.297-0.159-46%-0.766+158%-0.644+117%-0.690+133%
Total Gains Per Share---1.902-100%-0.2690%-0.0100%0.072-100%
Usd Book Value--6642000.0005095750.000+30%2567000.000+159%3878350.000+71%5233000.000+27%
Usd Book Value Change Per Share---1.902-100%-0.2690%-0.0100%0.065-100%
Usd Book Value Per Share--7.2655.574+30%0.452+1509%1.379+427%4.292+69%
Usd Dividend Per Share----0%-0%-0%0.008-100%
Usd Eps---2.155-1.604-26%-1.244-42%-1.400-35%-1.492-31%
Usd Free Cash Flow---2248000.000-1860750.000-17%-1779500.000-21%-2726950.000+21%-2221525.000-1%
Usd Free Cash Flow Per Share---2.459-2.035-17%-1.015-59%-1.391-43%-1.634-34%
Usd Free Cash Flow To Equity Per Share---2.0150.810-349%0.348-680%0.049-4194%0.268-850%
Usd Market Cap6491061.400-1%6545915.4401986790.473+229%6231290.116+5%7981586.738-18%5007791.842+31%
Usd Price Per Share7.100-1%7.1602.173+229%0.813+781%1.355+428%1.790+300%
Usd Profit---1970000.000-1466000.000-26%-2333494.000+18%-2834898.800+44%-2283249.400+16%
Usd Revenue---1250.000-100%75750.000-100%476500.000-100%927050.000-100%
Usd Total Gains Per Share---1.902-100%-0.2690%-0.0100%0.072-100%
 EOD+2 -5MRQTTM+14 -17YOY+16 -115Y+14 -1310Y+16 -17

4.2. Fundamental Score

Let's check the fundamental score of Titan Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.824
Price to Book Ratio (EOD)Between0-10.977
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than15.415
Current Ratio (MRQ)Greater than15.553
Debt to Asset Ratio (MRQ)Less than10.179
Debt to Equity Ratio (MRQ)Less than10.217
Return on Equity (MRQ)Greater than0.15-0.297
Return on Assets (MRQ)Greater than0.05-0.244
Total5/10 (50.0%)

4.3. Technical Score

Let's check the technical score of Titan Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5048.505
Ma 20Greater thanMa 507.082
Ma 50Greater thanMa 1007.271
Ma 100Greater thanMa 2006.822
OpenGreater thanClose7.102
Total2/5 (40.0%)



Latest Balance Sheet

Balance Sheet of 2024-03-31. Currency in USD. All numbers in thousands.

Summary
Total Assets8,086
Total Liabilities1,444
Total Stockholder Equity6,642
 As reported
Total Liabilities 1,444
Total Stockholder Equity+ 6,642
Total Assets = 8,086

Assets

Total Assets8,086
Total Current Assets8,018
Long-term Assets68
Total Current Assets
Cash And Cash Equivalents 6,773
Net Receivables 1,046
Other Current Assets 199
Total Current Assets  (as reported)8,018
Total Current Assets  (calculated)8,018
+/-0
Long-term Assets
Property Plant Equipment 68
Long-term Assets Other 0
Long-term Assets  (as reported)68
Long-term Assets  (calculated)68
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities1,444
Long-term Liabilities0
Total Stockholder Equity6,642
Total Current Liabilities
Short-term Debt 565
Accounts payable 348
Other Current Liabilities 519
Total Current Liabilities  (as reported)1,444
Total Current Liabilities  (calculated)1,432
+/- 12
Long-term Liabilities
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)0
+/-0
Total Stockholder Equity
Common Stock1
Retained Earnings -391,830
Other Stockholders Equity 398,471
Total Stockholder Equity (as reported)6,642
Total Stockholder Equity (calculated)6,642
+/-0
Other
Cash and Short Term Investments 6,773
Common Stock Shares Outstanding 782
Current Deferred Revenue12
Liabilities and Stockholders Equity 8,086
Net Debt -6,208
Net Working Capital 6,574
Short Long Term Debt Total 565



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-12-312006-09-302006-06-302006-03-312005-12-312005-09-302005-06-302005-03-312004-12-312004-09-302004-06-302004-03-312003-12-312003-09-302003-06-302003-03-312002-12-312002-09-302002-06-302002-03-312001-12-312001-09-302001-06-302001-03-312000-12-312000-09-302000-06-302000-03-311999-12-311999-09-301999-06-301999-03-311998-12-311998-09-301998-06-301998-03-311997-12-311997-09-301997-06-301997-03-311996-12-311996-09-301996-06-301996-03-311995-12-311995-09-301995-06-301995-03-31
> Total Assets 
4,700
4,700
4,700
4,700
11,800
8,800
19,700
16,400
10,600
13,800
7,900
25,600
20,000
17,700
15,000
12,200
15,400
12,400
9,700
47,400
85,801
83,513
80,626
118,442
118,442
114,473
110,488
107,132
98,882
91,920
84,039
75,926
69,293
62,730
56,321
49,008
58,137
50,932
45,580
38,626
33,140
26,505
21,200
19,737
25,154
21,695
18,748
15,040
11,791
18,675
14,390
30,844
25,739
19,467
13,496
5,700
5,700
5,700
1,400
3,726
7,450
2,086
8,547
4,752
3,218
8,841
6,551
10,217
7,509
10,054
10,744
24,827
23,532
16,908
15,520
18,423
16,123
14,249
13,216
20,851
18,388
17,313
14,909
13,287
11,996
25,298
23,535
18,667
13,074
9,414
12,740
8,905
8,905
4,617
11,854
14,095
14,095
6,761
5,304
9,522
13,262
9,762
8,018
8,087
13,824
11,507
9,637
7,994
10,318
8,319
6,276
4,058
2,168
812
9,999
8,086
8,086
8,0868,0869,9998122,1684,0586,2768,31910,3187,9949,63711,50713,8248,0878,0189,76213,2629,5225,3046,76114,09514,09511,8544,6178,9058,90512,7409,41413,07418,66723,53525,29811,99613,28714,90917,31318,38820,85113,21614,24916,12318,42315,52016,90823,53224,82710,74410,0547,50910,2176,5518,8413,2184,7528,5472,0867,4503,7261,4005,7005,7005,70013,49619,46725,73930,84414,39018,67511,79115,04018,74821,69525,15419,73721,20026,50533,14038,62645,58050,93258,13749,00856,32162,73069,29375,92684,03991,92098,882107,132110,488114,473118,442118,44280,62683,51385,80147,4009,70012,40015,40012,20015,00017,70020,00025,6007,90013,80010,60016,40019,7008,80011,8004,7004,7004,7004,700
   > Total Current Assets 
0
0
0
1,000
9,300
6,500
17,600
14,700
8,200
13,300
7,600
25,300
19,800
17,400
14,700
11,800
15,000
12,000
9,300
46,900
85,325
82,982
80,083
117,849
117,849
113,885
109,892
105,957
97,592
90,819
82,743
74,647
68,097
61,500
55,171
47,919
57,130
49,736
44,371
37,432
31,970
25,373
20,023
18,585
24,122
20,757
17,859
14,219
11,165
18,157
13,938
30,456
25,320
19,079
13,170
5,400
0
0
1,300
3,616
7,362
2,012
8,486
4,699
3,175
8,751
6,468
9,962
6,737
8,819
9,380
23,435
21,965
15,230
13,850
16,820
14,605
12,812
11,859
19,583
17,202
16,213
13,850
12,244
10,989
24,393
22,675
17,830
12,312
8,754
12,056
8,310
8,310
4,193
11,525
13,301
13,301
5,493
3,946
8,308
12,146
8,690
6,649
7,328
13,189
10,630
8,845
7,229
9,633
7,713
5,747
3,603
1,785
498
9,899
8,018
8,018
8,0188,0189,8994981,7853,6035,7477,7139,6337,2298,84510,63013,1897,3286,6498,69012,1468,3083,9465,49313,30113,30111,5254,1938,3108,31012,0568,75412,31217,83022,67524,39310,98912,24413,85016,21317,20219,58311,85912,81214,60516,82013,85015,23021,96523,4359,3808,8196,7379,9626,4688,7513,1754,6998,4862,0127,3623,6161,300005,40013,17019,07925,32030,45613,93818,15711,16514,21917,85920,75724,12218,58520,02325,37331,97037,43244,37149,73657,13047,91955,17161,50068,09774,64782,74390,81997,592105,957109,892113,885117,849117,84980,08382,98285,32546,9009,30012,00015,00011,80014,70017,40019,80025,3007,60013,3008,20014,70017,6006,5009,3001,000000
       Cash And Cash Equivalents 
0
0
0
900
300
100
500
1,400
3,400
11,400
5,500
24,400
19,100
16,800
14,100
11,700
14,800
11,800
9,100
46,500
6,227
6,278
6,334
20,300
20,300
11,316
6,232
5,772
4,602
6,298
7,037
7,155
8,431
18,544
7,473
6,832
23,078
5,223
5,956
5,463
6,160
5,270
6,829
9,142
15,283
7,393
9,099
9,613
1,846
2,999
863
25,614
24,340
18,173
12,204
4,700
0
0
700
3,300
1,643
1,452
6,401
3,180
800
6,092
2,772
5,406
2,308
4,104
5,062
18,102
17,606
11,176
8,998
11,798
10,239
8,853
7,450
15,470
13,423
11,499
9,690
7,857
5,762
19,305
16,489
14,006
10,870
8,350
11,688
7,522
7,522
1,614
8,427
9,295
9,295
2,292
921
5,223
8,038
5,498
4,073
5,413
11,629
9,680
7,418
6,037
8,138
6,420
4,450
2,937
1,136
105
8,096
6,760
6,773
6,7736,7608,0961051,1362,9374,4506,4208,1386,0377,4189,68011,6295,4134,0735,4988,0385,2239212,2929,2959,2958,4271,6147,5227,52211,6888,35010,87014,00616,48919,3055,7627,8579,69011,49913,42315,4707,4508,85310,23911,7988,99811,17617,60618,1025,0624,1042,3085,4062,7726,0928003,1806,4011,4521,6433,300700004,70012,20418,17324,34025,6148632,9991,8469,6139,0997,39315,2839,1426,8295,2706,1605,4635,9565,22323,0786,8327,47318,5448,4317,1557,0376,2984,6025,7726,23211,31620,30020,3006,3346,2786,22746,5009,10011,80014,80011,70014,10016,80019,10024,4005,50011,4003,4001,400500100300900000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
77,638
76,237
73,463
97,223
97,223
101,806
102,681
99,279
91,411
83,318
74,412
66,295
57,649
41,097
46,147
39,723
32,798
43,246
37,227
30,859
24,856
19,009
11,996
8,227
7,258
12,868
8,219
4,102
8,658
14,638
12,645
4,402
4,402
0
0
3,573
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
361
361
361
361
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000361361361361000000000000000000000000000000000003,573004,4024,40212,64514,6388,6584,1028,21912,8687,2588,22711,99619,00924,85630,85937,22743,24632,79839,72346,14741,09757,64966,29574,41283,31891,41199,279102,681101,80697,22397,22373,46376,23777,63800000000000000000000
       Net Receivables 
0
0
0
100
100
100
100
100
100
1,200
200
400
0
0
0
0
0
0
0
100
139
0
0
0
0
0
0
465
465
0
0
316
160
145
146
123
64
52
50
18
19
1,094
1,198
0
1,581
496
541
0
661
520
430
0
980
906
966
0
0
0
0
66
5,514
381
1,904
1,225
2,155
1,731
2,797
3,720
3,531
3,910
3,530
4,646
4,094
3,851
4,590
4,818
4,080
3,743
4,143
3,968
3,483
4,476
3,898
4,213
4,857
4,851
5,908
3,587
1,009
87
91
65
65
189
877
1,836
1,836
1,140
775
993
1,551
1,061
423
884
398
103
265
112
218
101
49
36
8
9
1,526
46
1,046
1,046461,5269836491012181122651033988844231,0611,5519937751,1401,8361,836877189656591871,0093,5875,9084,8514,8574,2133,8984,4763,4833,9684,1433,7434,0804,8184,5903,8514,0944,6463,5303,9103,5313,7202,7971,7312,1551,2251,9043815,514660000966906980043052066105414961,58101,1981,09419185052641231461451603160046546500000013910000000004002001,200100100100100100100000
       Other Current Assets 
0
0
0
0
8,900
6,300
17,000
13,200
4,700
700
1,900
500
700
600
600
100
200
200
200
300
1,321
467
286
326
326
763
979
441
1,579
1,203
1,294
881
1,857
1,714
1,405
1,241
1,190
1,215
1,138
1,092
935
1,094
1,198
1,216
1,581
496
541
504
661
520
430
440
980
906
966
700
0
0
600
250
205
179
181
294
220
928
899
836
898
805
788
687
265
203
262
204
286
216
266
145
296
238
262
174
370
237
278
237
433
317
277
362
723
291
928
646
908
744
941
1,094
1,493
1,162
1,080
522
816
648
846
480
749
544
512
314
406
229
244
199
199
1991992442294063145125447494808466488165221,0801,1621,4931,094941744908646928291723362277317433237278237370174262238296145266216286204262203265687788805898836899928220294181179205250600007009669069804404305206615045414961,5811,2161,1981,0949351,0921,1381,2151,1901,2411,4051,7141,8578811,2941,2031,5794419797633263262864671,3213002002002001006006007005001,9007004,70013,20017,0006,3008,9000000
   > Long-term Assets 
0
0
0
3,700
2,500
2,300
2,100
1,700
2,400
500
300
300
200
300
300
400
400
400
400
500
476
531
543
593
593
588
596
1,175
1,290
1,101
1,296
1,279
1,196
1,230
1,150
1,089
1,007
1,196
1,209
1,194
1,170
1,132
1,177
1,152
1,032
938
889
821
626
518
452
388
419
388
326
300
0
0
100
110
88
74
61
53
43
90
83
255
772
1,235
1,364
1,392
1,567
1,678
1,670
1,603
1,518
1,437
1,357
1,268
1,186
1,100
1,059
1,043
1,007
905
860
837
762
660
684
595
595
424
329
794
794
1,268
1,358
1,214
1,116
1,072
1,369
759
635
877
792
765
685
606
529
455
383
314
100
68
68
68681003143834555296066857657928776357591,3691,0721,1161,2141,3581,2687947943294245955956846607628378609051,0071,0431,0591,1001,1861,2681,3571,4371,5181,6031,6701,6781,5671,3921,3641,23577225583904353617488110100003003263884193884525186268218899381,0321,1521,1771,1321,1701,1941,2091,1961,0071,0891,1501,2301,1961,2791,2961,1011,2901,1755965885935935435314765004004004004003003002003003005002,4001,7002,1002,3002,5003,700000
       Property Plant Equipment 
0
0
0
800
800
800
800
800
700
300
300
300
300
200
300
400
500
400
400
400
460
515
527
593
593
588
596
575
690
801
996
979
896
930
850
789
707
896
1,059
1,044
1,020
982
867
788
668
574
525
457
441
425
417
388
419
388
326
300
0
0
100
110
88
74
61
53
43
90
83
255
772
1,235
1,364
1,392
1,567
1,678
1,670
1,603
1,518
1,437
1,357
1,268
1,186
1,100
1,059
1,043
1,007
905
860
837
762
660
684
595
595
424
329
794
794
1,268
1,208
1,214
1,116
1,072
1,369
759
635
877
792
717
637
558
481
407
335
133
100
68
68
68681001333354074815586377177928776357591,3691,0721,1161,2141,2081,2687947943294245955956846607628378609051,0071,0431,0591,1001,1861,2681,3571,4371,5181,6031,6701,6781,5671,3921,3641,23577225583904353617488110100003003263884193884174254414575255746687888679821,0201,0441,059896707789850930896979996801690575596588593593527515460400400400500400300200300300300300700800800800800800000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
16
16
16
0
0
0
0
600
600
300
300
300
300
300
300
300
300
300
150
150
150
150
310
364
364
364
364
364
185
93
35
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
150
0
0
0
208
141
0
0
0
48
48
48
48
0
48
0
0
0
0
000048048484848000141208000150000000000000000000000000000000000000000000000003593185364364364364364310150150150150300300300300300300300300300600600000016161600000000000000000000
> Total Liabilities 
0
0
0
9,300
4,200
3,600
3,400
3,800
11,100
10,000
7,900
7,200
1,400
1,200
1,200
1,600
1,600
1,700
1,200
1,900
2,199
1,579
2,975
2,463
2,463
2,914
2,520
5,764
3,473
3,759
3,418
3,945
3,935
3,991
3,785
3,341
4,172
2,633
3,324
3,672
4,467
3,430
4,489
3,136
3,213
2,999
4,138
3,394
3,302
3,246
2,883
4,256
4,400
5,042
4,555
3,900
0
0
2,300
3,933
7,825
4,233
10,699
10,805
13,644
25,826
24,101
30,296
31,199
33,049
37,875
47,955
26,580
14,762
14,498
12,663
11,841
10,786
8,965
12,240
14,197
15,327
5,992
6,297
6,520
7,618
8,273
5,476
2,467
1,876
8,702
8,048
8,048
5,930
6,365
7,264
7,264
7,332
7,964
8,089
7,986
8,202
8,915
4,555
3,844
2,760
2,141
2,856
2,436
2,652
2,726
2,695
2,480
1,846
1,866
1,444
1,444
1,4441,4441,8661,8462,4802,6952,7262,6522,4362,8562,1412,7603,8444,5558,9158,2027,9868,0897,9647,3327,2647,2646,3655,9308,0488,0488,7021,8762,4675,4768,2737,6186,5206,2975,99215,32714,19712,2408,96510,78611,84112,66314,49814,76226,58047,95537,87533,04931,19930,29624,10125,82613,64410,80510,6994,2337,8253,9332,300003,9004,5555,0424,4004,2562,8833,2463,3023,3944,1382,9993,2133,1364,4893,4304,4673,6723,3242,6334,1723,3413,7853,9913,9353,9453,4183,7593,4735,7642,5202,9142,4632,4632,9751,5792,1991,9001,2001,7001,6001,6001,2001,2001,4007,2007,90010,00011,1003,8003,4003,6004,2009,300000
   > Total Current Liabilities 
0
0
0
7,400
2,400
2,000
1,900
2,500
4,600
4,500
2,400
1,700
1,400
1,100
1,200
1,600
1,600
1,600
1,200
1,800
2,199
1,579
2,975
2,463
2,463
2,914
2,520
5,764
3,473
3,759
3,418
3,945
3,935
3,991
3,785
3,341
4,172
2,633
3,324
3,672
4,467
3,430
4,489
3,136
3,213
2,999
4,138
3,394
3,302
3,246
2,883
4,256
4,400
4,831
4,438
2,600
0
0
1,100
1,547
5,707
2,392
4,586
5,405
8,714
6,207
6,383
5,123
5,887
9,464
10,893
21,393
19,981
13,525
12,250
10,846
9,160
7,821
7,461
6,662
5,340
5,285
4,594
4,853
5,080
6,068
6,718
4,857
2,270
1,869
1,972
4,464
4,464
2,389
2,202
3,452
3,452
4,342
3,482
3,600
4,410
4,857
5,877
4,223
3,756
2,516
1,925
2,669
2,278
2,524
2,630
2,630
2,447
1,846
1,866
1,444
1,444
1,4441,4441,8661,8462,4472,6302,6302,5242,2782,6691,9252,5163,7564,2235,8774,8574,4103,6003,4824,3423,4523,4522,2022,3894,4644,4641,9721,8692,2704,8576,7186,0685,0804,8534,5945,2855,3406,6627,4617,8219,16010,84612,25013,52519,98121,39310,8939,4645,8875,1236,3836,2078,7145,4054,5862,3925,7071,5471,100002,6004,4384,8314,4004,2562,8833,2463,3023,3944,1382,9993,2133,1364,4893,4304,4673,6723,3242,6334,1723,3413,7853,9913,9353,9453,4183,7593,4735,7642,5202,9142,4632,4632,9751,5792,1991,8001,2001,6001,6001,6001,2001,1001,4001,7002,4004,5004,6002,5001,9002,0002,4007,400000
       Short-term Debt 
0
0
0
5,000
300
800
900
900
900
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
525
801
1,085
1,394
1,870
2,362
2,000
2,000
0
0
2,500
2,500
2,500
2,500
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
6,725
3,000
3,000
3,541
0
527
527
1,586
262
272
949
1,916
2,304
477
648
108
109
112
114
117
120
122
125
128
597
0
565
56505971281251221201171141121091086484772,3041,9169492722621,58652752703,5413,0003,0006,725000000000000000002,5002,5002,5002,500002,0002,0002,3621,8701,3941,085801525000000000000000000000000000000000000000000000000009009009008003005,000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
6,725
3,000
3,418
3,541
0
527
1,227
1,333
0
0
667
1,624
2,082
327
572
0
0
0
0
0
0
0
0
0
500
500
0
05005000000000005723272,0821,624667001,3331,22752703,5413,4183,0006,725000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
       Accounts payable 
0
0
0
700
800
800
700
700
700
1,100
1,600
800
900
600
600
400
900
800
200
800
1,042
281
1,335
1,304
1,304
552
590
894
545
849
1,175
1,901
1,897
1,579
746
1,505
783
634
678
689
723
590
679
518
661
247
682
561
390
565
443
557
1,098
585
544
500
0
0
400
335
4,116
625
1,730
2,457
4,963
3,002
3,026
4,789
4,060
5,405
4,878
3,767
5,039
4,405
5,293
5,118
4,291
3,832
4,362
4,408
3,948
4,786
4,038
4,158
4,258
4,848
4,954
3,015
1,537
928
712
1,464
821
575
686
2,612
1,526
1,025
1,383
1,401
1,332
1,528
1,750
1,253
768
439
386
795
468
443
812
695
567
597
407
348
348
3483484075975676958124434687953864397681,2531,7501,5281,3321,4011,3831,0251,5262,6126865758211,4647129281,5373,0154,9544,8484,2584,1584,0384,7863,9484,4084,3623,8324,2915,1185,2934,4055,0393,7674,8785,4054,0604,7893,0263,0024,9632,4571,7306254,116335400005005445851,0985574435653905616822476615186795907236896786347831,5057461,5791,8971,9011,1758495458945905521,3041,3041,3352811,0428002008009004006006009008001,6001,100700700700800800700000
       Other Current Liabilities 
0
0
0
1,700
1,300
400
300
900
3,000
3,400
800
900
500
500
600
1,200
700
800
1,000
1,000
1,157
1,298
1,640
1,159
1,159
2,362
1,930
2,870
2,928
1,906
2,243
2,044
2,038
2,412
3,039
1,836
3,389
1,999
2,646
2,983
3,744
2,840
3,810
2,618
2,552
2,752
3,456
2,833
2,912
2,681
2,440
3,699
3,302
4,246
3,894
2,100
0
0
700
687
300
682
1,462
1,078
1,389
1,205
1,357
334
1,827
462
1,815
751
1,817
693
729
411
464
495
516
583
632
499
556
695
822
1,220
1,764
1,842
733
941
1,260
3,584
643
875
890
4,100
1,086
1,731
1,837
1,927
2,129
1,413
1,823
1,960
1,893
1,627
1,113
1,467
1,485
1,799
1,437
1,617
1,657
1,105
850
0
519
51908501,1051,6571,6171,4371,7991,4851,4671,1131,6271,8931,9601,8231,4132,1291,9271,8371,7311,0864,1008908756433,5841,2609417331,8421,7641,2208226955564996325835164954644117296931,8177511,8154621,8273341,3571,2051,3891,0781,462682300687700002,1003,8944,2463,3023,6992,4402,6812,9122,8333,4562,7522,5522,6183,8102,8403,7442,9832,6461,9993,3891,8363,0392,4122,0382,0442,2431,9062,9282,8701,9302,3621,1591,1591,6401,2981,1571,0001,0008007001,2006005005009008003,4003,0009003004001,3001,700000
   > Long-term Liabilities 
0
0
0
1,900
1,800
1,600
1,500
1,300
6,500
5,500
5,500
5,500
0
100
0
0
0
100
804
100
0
0
0
0
650
653
645
641
0
140
0
941
941
11
91
0
234
45
32
1,091
1,241
1,241
1,241
877
1,241
1,241
1,241
877
1,241
1,241
1,241
0
1,241
211
117
1,300
0
0
1,200
2,386
2,118
1,841
6,113
5,400
4,930
19,619
17,718
25,173
25,312
23,585
26,982
26,562
6,599
1,237
2,248
1,817
2,681
2,965
1,504
5,578
8,857
10,042
1,398
1,444
1,440
1,550
1,555
619
197
7
6,730
0
3,584
3,541
4,163
0
3,812
2,990
4,482
4,489
3,576
3,345
3,038
332
88
244
216
187
158
128
96
65
33
0
0
0
0
0000336596128158187216244883323,0383,3453,5764,4894,4822,9903,81204,1633,5413,58406,73071976191,5551,5501,4401,4441,39810,0428,8575,5781,5042,9652,6811,8172,2481,2376,59926,56226,98223,58525,31225,17317,71819,6194,9305,4006,1131,8412,1182,3861,200001,3001172111,24101,2411,2411,2418771,2411,2411,2418771,2411,2411,2411,09132452340911194194101400641645653650000010080410000010005,5005,5005,5006,5001,3001,5001,6001,8001,900000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
12,515
13,005
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
6,725
0
0
3,541
4,146
3,787
3,242
2,698
3,872
4,019
3,500
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000003,5004,0193,8722,6983,2423,7874,1463,541006,7250000000000000000000000013,00512,51500000000000000000000000000000000000000000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
211
117
0
0
0
0
0
0
0
0
0
0
7,104
4,713
12,920
13,103
13,922
17,364
17,202
6,599
1,237
2,248
1,817
2,681
2,965
1,504
5,578
8,857
10,042
1,398
1,444
1,440
1,550
1,555
619
197
7
5
0
0
0
17
25
25
0
388
320
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000003203880252517000571976191,5551,5501,4401,4441,39810,0428,8575,5781,5042,9652,6811,8172,2481,2376,59917,20217,36413,92213,10312,9204,7137,104000000000011721100000000000000000000000000000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
17
0
0
0
150
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000150000170000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
> Total Stockholder Equity
0
0
0
-5,800
6,400
4,000
15,100
11,400
-1,700
2,600
-1,200
17,200
17,400
15,300
12,600
9,400
12,600
9,500
7,300
44,300
82,361
80,693
76,410
114,738
114,738
110,318
106,727
100,127
94,168
86,920
79,380
70,740
64,117
57,498
51,295
44,426
52,724
47,058
41,015
33,713
27,432
21,834
15,470
15,360
20,700
17,455
13,369
10,405
7,248
14,188
10,266
25,347
20,098
13,184
7,700
1,800
0
0
-900
-1,448
-1,616
-3,388
-3,393
-6,053
-10,426
-16,985
-17,550
-20,079
-23,690
-22,995
-27,131
-23,128
-3,048
2,146
1,022
5,760
4,282
3,463
4,251
8,611
4,191
1,986
8,917
6,990
5,476
17,680
15,262
13,191
10,607
7,538
4,038
857
857
-1,313
5,489
6,831
6,831
-571
-2,660
1,433
5,276
1,560
-897
3,532
9,980
8,747
7,496
5,138
7,882
5,667
3,550
1,363
-312
-1,034
8,133
6,642
6,642
6,6426,6428,133-1,034-3121,3633,5505,6677,8825,1387,4968,7479,9803,532-8971,5605,2761,433-2,660-5716,8316,8315,489-1,3138578574,0387,53810,60713,19115,26217,6805,4766,9908,9171,9864,1918,6114,2513,4634,2825,7601,0222,146-3,048-23,128-27,131-22,995-23,690-20,079-17,550-16,985-10,426-6,053-3,393-3,388-1,616-1,448-900001,8007,70013,18420,09825,34710,26614,1887,24810,40513,36917,45520,70015,36015,47021,83427,43233,71341,01547,05852,72444,42651,29557,49864,11770,74079,38086,92094,168100,127106,727110,318114,738114,73876,41080,69382,36144,3007,3009,50012,6009,40012,60015,30017,40017,200-1,2002,600-1,70011,40015,1004,0006,400-5,800000
   Common Stock
0
0
0
0
0
0
0
0
0
0
0
0
0
-5,000
-5,000
-5,000
-5,000
58,200
58,400
98,700
145,362
146,017
150,123
190,763
190,763
191,612
191,613
191,684
191,685
191,686
191,685
191,680
191,680
191,690
191,727
195,331
209,810
209,834
209,889
210,264
210,287
210,346
210,362
214,331
224,052
224,038
224,083
224,221
224,317
234,524
234,555
255,429
255,402
255,403
255,403
255,400
0
0
255,900
256,436
256,436
256,436
256,436
256,436
256,436
256,436
256,436
256,436
256,436
258,539
262,052
265,986
279,560
279,560
279,560
284,485
284,485
284,448
284,449
289,196
289,182
289,182
297,828
297,828
297,828
297,855
297,855
297,855
297,855
297,855
297,855
297,855
297,855
297,855
39
13
13
14
17
57
93
97
117
7
10
10
10
10
12
15
15
15
15
15
15
0
1
10151515151515121010101071179793571714131339297,855297,855297,855297,855297,855297,855297,855297,855297,855297,828297,828297,828289,182289,182289,196284,449284,448284,485284,485279,560279,560279,560265,986262,052258,539256,436256,436256,436256,436256,436256,436256,436256,436256,436256,436255,90000255,400255,403255,403255,402255,429234,555234,524224,317224,221224,083224,038224,052214,331210,362210,346210,287210,264209,889209,834209,810195,331191,727191,690191,680191,680191,685191,686191,685191,684191,613191,612190,763190,763150,123146,017145,36298,70058,40058,200-5,000-5,000-5,000-5,0000000000000000
   Retained Earnings Total Equity00000000000-371,600-369,920-367,279-364,194-359,262-354,621-349,037-345,096-342,293-337,096-332,579-329,075-326,745-325,876-323,271-319,611-315,420-311,969-308,964-306,637-304,017-315,945-314,099-311,805-309,998-307,7170-302,347-303,063-302,221-300,41700000000-292,050-291,24600000000000000000000000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
-500
-500
-900
-900
-900
-900
-200
-500
-200
-200
-300
-300
-200
-200
-500
-458
-359
-37
-415
-563
670
1,675
1,096
101
-232
-514
-249
-368
-318
-279
-211
-189
-301
-187
-133
-117
-16
-20
-27
3
15
46
10
13
-1
8
1
-2,129
-2,129
-2,129
0
0
0
0
-2,450
0
0
0
-2,535
-2,535
0
0
-2,430
-2,430
0
0
-2,447
-2,447
0
0
-2,554
-2,554
0
0
-2,907
-2,907
0
0
-3,265
-3,265
0
0
-3,642
-3,642
0
0
-4,059
-4,059
0
0
-4,439
-4,439
0
0
-4,683
-4,683
0
0
0
0
0
0
0
0
0
0
0
0
0
-1
0
-1
-10-10000000000000-4,683-4,68300-4,439-4,43900-4,059-4,05900-3,642-3,64200-3,265-3,26500-2,907-2,90700-2,554-2,55400-2,447-2,44700-2,430-2,43000-2,535-2,535000-2,4500000-2,129-2,129-2,12918-1131046153-27-20-16-117-133-187-301-189-211-279-318-368-249-514-2321011,0961,675670-563-415-37-359-458-500-200-200-300-300-200-200-500-200-900-900-900-900-500-50000000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
17,825
18,064
0
0
0
0
0
0
0
0
21,692
22,018
22,078
22,149
0
22,726
22,802
22,894
23,261
23,593
23,842
24,044
24,300
24,721
25,103
25,794
26,273
27,175
27,577
334,525
339,397
340,138
341,708
342,419
350,413
359,804
360,725
363,180
370,804
379,890
380,337
0
0
0
0
0
0
0
0
0
0
0
00000000000380,337379,890370,804363,180360,725359,804350,413342,419341,708340,138339,397334,52527,57727,17526,27325,79425,10324,72124,30024,04423,84223,59323,26122,89422,80222,726022,14922,07822,01821,6920000000018,06417,82500000000000000000000000000000000000000000000000000000000000000000
   Treasury Stock000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
25,400
41,100
41,800
55,700
56,400
56,500
56,500
56,600
60,900
63,800
63,600
63,700
63,800
69,800
6,500
6,600
6,500
262,608
6,467
6,838
8,596
8,596
7,353
7,544
7,776
7,761
7,877
7,916
7,920
7,946
7,948
7,837
9,047
7,984
7,961
8,019
9,327
8,062
8,046
8,048
9,263
8,316
8,499
8,677
10,118
9,194
9,475
9,837
11,508
12,899
13,667
14,083
13,400
0
0
14,300
17,477
15,164
15,238
15,617
19,791
17,395
17,825
18,064
20,863
19,985
20,301
20,666
23,461
21,519
21,649
21,670
24,246
22,018
22,078
22,149
25,142
22,726
22,802
22,894
26,526
23,593
23,842
24,044
27,942
24,721
25,103
25,794
0
30,332
27,577
334,525
0
343,836
341,708
342,419
355,096
359,804
360,725
363,180
370,804
379,890
380,337
381,001
381,183
386,465
386,709
387,230
387,609
387,609
388,473
397,978
0
398,471
398,4710397,978388,473387,609387,609387,230386,709386,465381,183381,001380,337379,890370,804363,180360,725359,804355,096342,419341,708343,8360334,52527,57730,332025,79425,10324,72127,94224,04423,84223,59326,52622,89422,80222,72625,14222,14922,07822,01824,24621,67021,64921,51923,46120,66620,30119,98520,86318,06417,82517,39519,79115,61715,23815,16417,47714,3000013,40014,08313,66712,89911,5089,8379,4759,19410,1188,6778,4998,3169,2638,0488,0468,0629,3278,0197,9617,9849,0477,8377,9487,9467,9207,9167,8777,7617,7767,5447,3538,5968,5966,8386,467262,6086,5006,6006,50069,80063,80063,70063,60063,80060,90056,60056,50056,50056,40055,70041,80041,10025,400000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue184
Cost of Revenue-112
Gross Profit7272
 
Operating Income (+$)
Gross Profit72
Operating Expense-7,349
Operating Income-7,277-7,277
 
Operating Expense (+$)
Research Development1,913
Selling General Administrative5,548
Selling And Marketing Expenses112
Operating Expense7,3497,573
 
Net Interest Income (+$)
Interest Income5
Interest Expense-0
Other Finance Cost-40
Net Interest Income45
 
Pretax Income (+$)
Operating Income-7,277
Net Interest Income45
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-5,569-8,985
EBIT - interestExpense = -7,277
-5,569
-5,569
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-7,277-5,569
Earnings Before Interest and Taxes (EBITDA)-7,165
 
After tax Income (+$)
Income Before Tax-5,569
Tax Provision-0
Net Income From Continuing Ops-6,165-5,569
Net Income-5,569
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses7,461
Total Other Income/Expenses Net1,708-45
 

Technical Analysis of Titan Pharmaceuticals Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Titan Pharmaceuticals Inc. The general trend of Titan Pharmaceuticals Inc is BEARISH with 14.3% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Titan Pharmaceuticals Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-14.3%) Bearish trend (14.3%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Titan Pharmaceuticals Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 7.402 < 8.29 < 9.07.

The bearish price targets are: 6.28 > 5.49 > 5.25.

Tweet this
Titan Pharmaceuticals Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Titan Pharmaceuticals Inc. The current mas is .

The long score for the Moving Averages is 6/14.
The longshort score for the Moving Averages is -2/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Titan Pharmaceuticals Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Titan Pharmaceuticals Inc. The current macd is -0.01489336.

The long score for the Moving Average Convergence/Divergence (MACD) is 2/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 0/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Titan Pharmaceuticals Inc price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Titan Pharmaceuticals Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Titan Pharmaceuticals Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Titan Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) ChartTitan Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Titan Pharmaceuticals Inc. The current adx is 20.23.

The long score for the Directional Movement Index (DMI) is 2/7.
The longshort score for the Directional Movement Index (DMI) is 2/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Titan Pharmaceuticals Inc shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bullish trend could be forming. +1
Titan Pharmaceuticals Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Titan Pharmaceuticals Inc. The current sar is 6.69637117.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Titan Pharmaceuticals Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Titan Pharmaceuticals Inc. The current rsi is 48.50. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -3/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
Titan Pharmaceuticals Inc Daily Relative Strength Index (RSI) ChartTitan Pharmaceuticals Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Titan Pharmaceuticals Inc. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Titan Pharmaceuticals Inc price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Titan Pharmaceuticals Inc Daily Stochastic Oscillator ChartTitan Pharmaceuticals Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Titan Pharmaceuticals Inc. The current cci is 13.52.

Titan Pharmaceuticals Inc Daily Commodity Channel Index (CCI) ChartTitan Pharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Titan Pharmaceuticals Inc. The current cmo is -6.09538024.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Titan Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) ChartTitan Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Titan Pharmaceuticals Inc. The current willr is -80.08130081.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Titan Pharmaceuticals Inc Daily Williams %R ChartTitan Pharmaceuticals Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Titan Pharmaceuticals Inc.

Titan Pharmaceuticals Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Titan Pharmaceuticals Inc. The current atr is 0.50573475.

Titan Pharmaceuticals Inc Daily Average True Range (ATR) ChartTitan Pharmaceuticals Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Titan Pharmaceuticals Inc. The current obv is 1,621,292.

Titan Pharmaceuticals Inc Daily On-Balance Volume (OBV) ChartTitan Pharmaceuticals Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Titan Pharmaceuticals Inc. The current mfi is 65.06.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Titan Pharmaceuticals Inc Daily Money Flow Index (MFI) ChartTitan Pharmaceuticals Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Titan Pharmaceuticals Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-27STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-11-29WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-11-30STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-05STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-06CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-13RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-14STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-15STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-12-18CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-19STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-12-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-29CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-02STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-09RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-10DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-01-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-17WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-23DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-25CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-26MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-31MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-01DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-02MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-02-05STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-07STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-08CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-12STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-20CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-22WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-27MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-29MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-07MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-11STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-13STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-14DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-18STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-19MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-20DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-21DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-03-22DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-28STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-02STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-08SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-10MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-04-11STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-12CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-17CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside

6.3. Candlestick Patterns

Titan Pharmaceuticals Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Titan Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5048.505
Ma 20Greater thanMa 507.082
Ma 50Greater thanMa 1007.271
Ma 100Greater thanMa 2006.822
OpenGreater thanClose7.102
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Titan Pharmaceuticals Inc with someone you think should read this too:
  • Are you bullish or bearish on Titan Pharmaceuticals Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Titan Pharmaceuticals Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Titan Pharmaceuticals Inc

I send you an email if I find something interesting about Titan Pharmaceuticals Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Titan Pharmaceuticals Inc.

Receive notifications about Titan Pharmaceuticals Inc in your mailbox!